News and Events

Stay up to date on our current affairs.

Jun 21,
2018
Mitsubishi Tanabe Pharma America to Present Data on RADICAVA® (edaravone) at the European Network for the Cure of ALS (ENCALS) Annual Meeting
May 7,
2018
Mitsubishi Tanabe Pharma America Marks One-Year Anniversary of Only FDA-Approved ALS Treatment Option in the Last 20 Years
Apr 18,
2018
Mitsubishi Tanabe Pharma America and NeuroDerm Announce Parkinson’s Disease Presentations at American Academy of Neurology Annual Meeting
Apr 18,
2018
Mitsubishi Tanabe Pharma America Announces ALS Presentations at American Academy of Neurology Annual Meeting
Apr 9,
2018
Health Canada Accepts Mitsubishi Tanabe Pharma Corporation’s NDS Filing for Edaravone to Treat ALS, Grants Priority Review
Dec 20,
2017
Mitsubishi Tanabe Pharma America Initiates Independent Research Program for RADICAVA® (edaravone)
Dec 5,
2017
Mitsubishi Tanabe Pharma America to Present Data on RADICAVA® (Edaravone) At 28th International Symposium on ALS/MND in Boston
Nov 30,
2017
Mitsubishi Tanabe Pharma America Announces Addition of RADICAVA® (edaravone) to U.S. Department of Veterans Affairs National Formulary
Nov 21,
2017
Mitsubishi Tanabe Pharma America Expands Executive Leadership Team, Names Kevin O’Brien as Vice President of Market Access
Nov 16,
2017
Mitsubishi Tanabe Pharma America Announces 1,000 People with ALS Have Received FDA-Approved Treatment Option in First Three Months Available
Sep 7,
2017
Comprehensive Edaravone Clinical Program Data Published as Supplement to Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Journal
Sep 6,
2017
Mitsubishi Tanabe Pharma America Signs Agreement with Option Care For National Home Infusion Services
Aug 31,
2017
Mitsubishi Tanabe Pharma America Statement on Access to RADICAVA™ (edaravone)
Aug 9,
2017
MTPA Perspective Regarding Medicare Coverage
Aug 8,
2017
FIRST FDA-APPROVED TREATMENT FOR ALS IN 22 YEARS NOW AVAILABLE IN U.S.
Aug 1,
2017
MT Pharma America Announces Corporate Name Change to Mitsubishi Tanabe Pharma America
Jul 25,
2017
Mitsubishi Tanabe Pharma America Begins Patient Insurance Benefits Investigation Process in Advance of Availability of RADICAVA™ (Edaravone)
Jun 30,
2017
Mitsubishi Tanabe Pharma America Enrolls More Than 700 Sites of Care in Newly Created National Infusion Center Directory for ALS Patients
May 18,
2017
Mitsubishi Tanabe Pharma America Presents 12-Month RADICAVA™ (Edaravone) and Amyotrophic Lateral Sclerosis Data at the European Network for the Cure of ALS (ENCALS) Annual Meeting
May 5,
2017
Mitsubishi Tanabe Pharma America Announces FDA Approval of RADICAVA™ (Edaravone), the First New Treatment Option for ALS in More Than 20 Years